Literature DB >> 22026253

Study of interleukin-6 production in Alzheimer's disease.

Inimioara Mihaela Cojocaru1, M Cojocaru, Gabriela Miu, Violeta Sapira.   

Abstract

There is a growing body of evidence which supports the hypothesis of faulty immune regulation and autoimmunity or inflammatory processes as viable mechanisms of the pathogenesis of Alzheimer's disease. The aim of this study was to evaluate the IL-6 level in serum of patients with AD and to analyze the correlation between IL-6 and this disease. Serum samples from 47 patients with clinically diagnosed Alzheimer's disease (27 women and 20 men, mean age 70.43 +/- 10.82 years, range 40-89 years) as compared to 47 controls (25 women and 22 men, mean age 70.17 +/- 10.64 years, range 40-89 years) were analyzed for IL-6 by ELISA (R&D Systems). The interleukin-6 levels were significantly higher in AD patients (234 pg/ml, range 85-567 pg/ml) as compared to control group (67 pg/ml, range 38-181 pg/ml); p < 0.001. It was evident from the study that increased production of IL-6 cytokine is found in AD patients, suggesting abnormal cellular immunity in these patients. Interleukin-6 plays a role in the pathogenesis of Alzheimer's disease. Our results suggest that high peripheral IL-6 secretion levels may be responsible for acute-phase proteins observed in the serum of AD patients. We find these results very promising for the consideration of future treatment of AD patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22026253

Source DB:  PubMed          Journal:  Rom J Intern Med        ISSN: 1220-4749


  32 in total

Review 1.  Interleukin 6 and cognitive dysfunction.

Authors:  Isabel Trapero; Omar Cauli
Journal:  Metab Brain Dis       Date:  2014-04-30       Impact factor: 3.584

2.  IL-6 regulation of synaptic function in the CNS.

Authors:  Donna L Gruol
Journal:  Neuropharmacology       Date:  2014-11-22       Impact factor: 5.250

3.  BAY 11-7082 inhibits the secretion of interleukin-6 by senescent human microglia.

Authors:  Maxwell Cook; Houmin Lin; Sandeep K Mishra; Gavin Y Wang
Journal:  Biochem Biophys Res Commun       Date:  2022-05-30       Impact factor: 3.322

4.  p38 MAPK Is a Major Regulator of Amyloid Beta-Induced IL-6 Expression in Human Microglia.

Authors:  Houmin Lin; Steven Grant Dixon; Wei Hu; Eric D Hamlett; Junfei Jin; Adviye Ergul; Gavin Y Wang
Journal:  Mol Neurobiol       Date:  2022-06-13       Impact factor: 5.682

5.  A Dichotomous Role for FABP7 in Sleep and Alzheimer's Disease Pathogenesis: A Hypothesis.

Authors:  Hope Needham; Grace Torpey; Carlos C Flores; Christopher J Davis; William M Vanderheyden; Jason R Gerstner
Journal:  Front Neurosci       Date:  2022-06-30       Impact factor: 5.152

6.  Early manifestation of mild cognitive impairment in B-cell non-Hodgkin's lymphoma patients receiving CHOP and rituximab-CHOP chemotherapy.

Authors:  Mohd Ashif Khan; Kamlesh Garg; Dinesh Bhurani; Nidhi Bharal Agarwal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-08-27       Impact factor: 3.000

Review 7.  Can infections cause Alzheimer's disease?

Authors:  Francis Mawanda; Robert Wallace
Journal:  Epidemiol Rev       Date:  2013-01-24       Impact factor: 6.222

Review 8.  Glaucoma: an extension of various chronic neurodegenerative disorders.

Authors:  Vishal Jindal
Journal:  Mol Neurobiol       Date:  2013-02-10       Impact factor: 5.590

Review 9.  Neuroinflammatory Signaling in the Pathogenesis of Alzheimer's Disease.

Authors:  Md Sahab Uddin; Md Tanvir Kabir; Maroua Jalouli; Md Ataur Rahman; Philippe Jeandet; Tapan Behl; Athanasios Alexiou; Ghadeer M Albadrani; Mohamed M Abdel-Daim; Asma Perveen; Ghulam Md Ashraf
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

10.  Using BAC transgenesis in zebrafish to identify regulatory sequences of the amyloid precursor protein gene in humans.

Authors:  Leighcraft A Shakes; Hansen Du; Hope M Wolf; Charles Hatcher; Derek C Norford; Patricia Precht; Ranjan Sen; Pradeep K Chatterjee
Journal:  BMC Genomics       Date:  2012-09-04       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.